Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects
Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 902-914
DOI: 10.1021/acs.jmedchem.4c01322 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 06.01.2025. Verfasst von Yaoxiang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Inflammation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Interleukin-1 receptor-associated kinase 4 (IRAK4) is involved in various inflammation-related diseases. Both the kinase and scaffolding functions of IRAK4 initiate pro-inflammatory factor transcription and expression. The scaffolding function of IRAK4 is essential for Myddosome assembly and NF-κB activation. Conventional small-molecule inhibitors effectively inhibit the kinase function of IRAK4 but do not block its scaffolding function. Recently, various IRAK4 degraders have shown promising therapeutic potential in inflammatory diseases. The most advanced IRAK4-selective degrader, KT-474 (SAR444656), significantly reduced inflammatory biomarker levels in patients and demonstrated high safety and tolerability. This perspective introduces and discusses the physiological biology of IRAK4, its associated diseases, and the current development of IRAK4 degraders, thereby offering insights into future research directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, China.
- School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
- Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310000, China.
- School of Medicine, Zhejiang University City College, Huzhou Road, Hangzhou 310015, China.
ORCID-Profile: Jie Li, Lingfeng Chen
Förderung
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Health Commission of Zhejiang Province
Zitieren
APA
Lin, Y., Zheng, L., Xu, Y., Wang, X., Li, J., Zheng, L., Liang, G., & Chen, L. (2025). Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects. Journal of Medicinal Chemistry, 68(2), 902-914. https://doi.org/10.1021/acs.jmedchem.4c01322
Vancouver
Lin Y, Zheng L, Xu Y, Wang X, Li J, Zheng L, et al. Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects. Journal of Medicinal Chemistry. 2025;68(2):902-914. doi:10.1021/acs.jmedchem.4c01322
BibTeX
@article{Lin2025,
author = {Lin, Yaoxiang and Zheng, Lulu and Xu, Ying and Wang, Xinyan and Li, Jie and Zheng, Lei and Liang, Guang and Chen, Lingfeng},
title = {Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {2},
pages = {902--914},
doi = {10.1021/acs.jmedchem.4c01322}
}
EUVIMED